- TWD2.60bn
- TWD3.11bn
- TWD1.67bn
- 44
- 35
- 39
- 32
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.04 | ||
Price to Tang. Book | 1.29 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.56 | ||
EV to EBITDA | 23.97 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 1.94% | ||
Return on Equity | 3.84% | ||
Operating Margin | 3.43% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | TWDm | 1,484.41 | 1,263.38 | 1,483.52 | 1,191.98 | 1,670.03 | n/a | n/a | 6.11% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -7.96 | -69.1 | +193.03 | -99.24 | +7009.47 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
OK Biotech Co Ltd is a Taiwan-based company mainly engaged in the manufacture and distribution of medical supplies and products. The Company primarily provides home medical blood glucose meters and disposable blood glucose test strips. Its products are mainly catering to diabetes patients, as well as doctors or nurses in hospitals and clinics for monitoring blood glucose levels. The Company distributes its products in Americas, Taiwan and other Asian markets.
Directors
- Chia To Lai CHM
- Qingxiang Huang VCH
- Xiuqin Wang DGM
- Qizheng Hou OTH
- Weijie Chen DRC
- Dequan Zhang DRC
- Guquan Chen IND
- Lifen He IND
- Shiyi Lin IND
- Zhilong Lin IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 27th, 2004
- Public Since
- December 30th, 2010
- No. of Employees
- 62
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Taiwan Stock Exchange
- Shares in Issue
- 147,059,000

- Address
- No.91, Section 2, Gongdao 5th Road, HSINCHU, 300
- Web
- https://www.okbiotech.com/
- Phone
- +886 35160258
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 4155
OK Biotech Co Ltd Annual Shareholders Meeting
OK Biotech Co Ltd Annual Shareholders Meeting
Q2 2025 OK Biotech Co Ltd Earnings Release
Similar to 4155
Apex Biotechnology
Taiwan Stock Exchange
Wellell
Taiwan Stock Exchange
Bionime
Taiwan Stock Exchange
Bonraybio Co
Taiwan Stock Exchange
CHC Healthcare
Taiwan Stock Exchange
FAQ
As of Today at 22:25 UTC, shares in OK Biotech Co are trading at TWD17.70. This share price information is delayed by 15 minutes.
Shares in OK Biotech Co last closed at TWD17.70 and the price had moved by -25.79% over the past 365 days. In terms of relative price strength the OK Biotech Co share price has underperformed the FTSE Developed Asia Pacific Index by -23.68% over the past year.
The overall consensus recommendation for OK Biotech Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe OK Biotech Co dividend yield is 1.69% based on the trailing twelve month period.
Last year, OK Biotech Co paid a total dividend of TWD0.30, and it currently has a trailing dividend yield of 1.69%. We do not have any data on when OK Biotech Co is to next pay dividends.
We do not have data on when OK Biotech Co is to next pay dividends. The historic dividend yield on OK Biotech Co shares is currently 1.69%.
To buy shares in OK Biotech Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD17.70, shares in OK Biotech Co had a market capitalisation of TWD2.60bn.
Here are the trading details for OK Biotech Co:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 4155
Based on an overall assessment of its quality, value and momentum OK Biotech Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OK Biotech Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -20.53%.
As of the last closing price of TWD17.70, shares in OK Biotech Co were trading -21.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The OK Biotech Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD17.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
OK Biotech Co's management team is headed by:
- Chia To Lai - CHM
- Qingxiang Huang - VCH
- Xiuqin Wang - DGM
- Qizheng Hou - OTH
- Weijie Chen - DRC
- Dequan Zhang - DRC
- Guquan Chen - IND
- Lifen He - IND
- Shiyi Lin - IND
- Zhilong Lin - IND